Comments for ANGO
TheStreet.com Network:
TheStreet.com
|
MainStreet.com
|
BankingMyWay.com
|
Geezeo Budget Planner
|
RealMoney
|
Dividend.com
Log In
Sign up
Go to
Answers
Articles
Top Performing Portfolios
Top Rated Portfolios
About Stockpickr
Professional Portfolios
Forums
Do-It-Yourself Portfolios
Video
How to Use Stockpickr
Spotlight Portfolios
Buying Opportunities
Cramer's Worst Case Scenario
Cramer's Next Bank Seizures
Cramer's Bailout Plan Win...
Cramer's Tech Take
I'm Feeling Lucky
Cash Cow Stock Picks
Top Dividend Plays
Barron's Activist Stocks
Club of Elite Banks
Insiders & Buybacks
More Spotlights>>
Active Trader
System Trades of the Day
Unusual Volume System
The Mega Gap System
The Takeover Targets S...
First Day of the Month
The QQQQCrash+ with St...
The QQQQ Crash Plus
The Blizzard System
The Last Week of the Year
The QQQQ Sweet Spot
More Traders>>
Most Viewed Portfolios
Warren Buffett
10 Short Squeezes
George Soros
T. Boone Pickens - BP ...
Carl Icahn
High Yield Warren Buff...
Mad Money Buybacks
Renaissance Technologies
Chinese Rocket Stocks
Mohnish Pabrai
More>>
Today's List of Portfolios
TSC Ratings' Downgrades
TSC Ratings' Upgrades
Analyst Downgrades
Analyst Upgrades
TheStreet.com TV Video...
TheStreet.com TV Video...
TheStreet.com TV Video...
TheStreet.com TV Video...
TheStreet.com TV Video...
TheStreet.com TV Video...
More>>
My Stockpickr
Comments for ANGO
Added By
Comments
Type
Date Added
casecollectibles
i love angio....made me some mad money today
Love
June 06, 2007
Pam
Rating: BUY Target: $29 Sector: Healthcare We have selected AngioDynamics as the top pick in our MedTech universe for 2007. In our judgment, there are several catalysts converging that will ignite share price appreciation in the New Year. Specifically, the pending RITA acquisition affords the company opportunities, both in the U.S. and Europe, to fuel annual sales growth beyond our original 25% projection. RITA broadens AngioDynamics’ product assortment and leverages its formidable sales force, provides access to larger market opportunities with differentiated products, and AngioDynamics gains access to additional R&D with expertise in tumor ablation and port technology. In addition, we cite the ramp of Sotradecol sales in the U.S. largely driven by the sole distributorship arrangement, introduction of new products with higher margins, resolution of the Diomed case and entrance into new markets, including oncology.
Love
January 06, 2007
Join TD Ameritrade.